注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

zliming2004的博客

新药研发与药物合成

 
 
 

日志

 
 
 
 

Vertex收购 Concert的囊性纤维化药物CTP-656  

2017-03-13 15:13:25|  分类: 药物化学 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

Vertex收购 Concert的囊性纤维化药物CTP-656

2017-03-07

Vertex Pharmaceuticals will pay up to $250 million for Concert Pharmaceuticals’ cystic fibrosis drug CTP-656. Currently in Phase II clinical trials, the drug is a deuterated version of Vertex’s own compound ivacaftor, which it sells under the name Kalydeco.

Like ivacaftor, CTP-656 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. Substituting deuterium atoms for specific hydrogens in the structure generates a novel compound with altered pharmacokinetic properties. Notable is its longer half-life, which means that CTP-656 may need to be given only once per day versus two times daily for Kalydeco.

For Concert, the deal is a validation of its deuterium chemistry approach to drug design and an opportunity for CTP-656 to advance into late-stage development and commercialization. Vertex already leads the cystic fibrosis drug market with Kalydeco and Orkambi, a CFTR potentiator combination it launched in 2015. Sales of the two products, which are used by people with specific mutations in the CFTR gene, reached $1.7 billion in 2016.

Vertex will acquire rights to all of Concert’s other cystic fibrosis research and preclinical programs. Concert intends to use the money to help support itself through 2021, expand its pipeline, and advance its deuterated JAK 1/2 inhibitor CTP-543, now in Phase II testing against the autoimmune disease alopecia areata.

The deal brings at least three benefits to Vertex, Leerink stock analyst Geoffrey C. Porges told clients in a report. It removes a potential competitor and increases the company’s cystic fibrosis franchise with a new compound that can improve its existing therapy combinations and extend its intellectual property protection by at least five years.

Concert’s shareholders and regulators must still approve the sale of the drug to Vertex.

Concert posted data showing its modified version of Kalydeco could outdo its reference med in a small test back in 2015.

Vertex could pay out as much as $250 million to gain full access to Concert Pharmaceuticals’ midstage cystic fibrosis (CF) candidate CTP-656, a tweaked version of its own Kalydeco, as it eyes combo uses that target the underlying causes of the fatal disease while taking over a potential competitor product.  

The deal sees Vertex, which is looking to build up its marketed CF franchise, pay $160 million in cash with $90 million in biobucks also lined up for the future.

The pharma gets CTP-656 for its moneyan investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that the company hopes it can use as part of a once-daily combo of CFTR modulators that treat the underlying cause of CF.

This will dovetail with its CF meds: Kalydeco (ivacaftor) and more recently its combo therapy Orkambi (lumacaftor/ivacaftor).

Kalydeco is suitable for CF patients with the Gly551Asp mutation in the CFTR generepresenting just 4% to 5% of the total patient populationbut adding lumacaftor means that it can be prescribed for about 45% of patients. The second ingredient targets those carrying two copies of the much more common F508del mutation.

CTP-656 was in fact developed by Concert through the use of its deuterium chemistry to modify ivacaftor as it looked to make a better version of the drug. The big idea at Concert is taking approved or previously studied drugs and reformulating them with deuterium to boost their safety, tolerability and efficacy, creating new, and patentable, products in the process.

Back in 2015, the biotech posted data showing its treatment lasted longer than Vertex’ med in a small, early-stage trial. Clearly, Vertex wants to get its hands fully on this boosted version of its drug.

“With Vertex’s clinical and commercial expertise in CF, this agreement provides the optimal pathway to rapidly advance the development of CTP-656 for the benefit of cystic fibrosis patients,” said Roger Tung, president and CEO of Concert Pharmaceuticals.

“The financial strength provided to Concert by this agreement will allow us to advance [autoimmune med] CTP-543 into pivotal testing and broaden our proprietary development pipeline.”

Concert is currently conducting a phase 2 study of CTP-656 in people with CF who have gating mutations. As part of the agreement, Vertex gains all rights to Concert’s other CF research and preclinical programs.
Analysts at Leerink said they saw the deal as a positive for Vertex, saying in a note: "First, most obviously it removes a potential competitor, and, more importantly, a potential combination partner for other entrants who may possess a CFTR corrector. It signals Vertex's willingness to enhance and improve its existing franchise and portfolio in CF, rather than fret over "not-invented-here" considerations.

"Second, it offers a potentially improved profile for future multi-drug CF combinations. Third, it can extend the duration of Vertex's CF combinations even longer, given likely composition-of-matter exclusivity for Kalydeco of 2027 in the U.S. and 2025 in Europe, compared to 2032-plus in the U.S. and Europe for CTP-656.

"CTP-656 was one of numerous CF competitors in early clinical trials that have been advanced in parallel with Vertex’s race to concoct a triple-therapy regimen for the majority of CF patients, and today’s news signals, in our view, the willingness of Vertex to defend its dominant and valuable position in the market category."

Concert rocketed up more than 77% on the news while Vertex edged down 0.5%. 

  评论这张
 
阅读(1)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017